Highly differentiated CD4 T cells Unequivocally Identify Primary Resistance and Risk of Hyperprogression to PD-L1/PD-1 Immune Checkpoint Blockade in Lung Cancer
M. Zuazo-Ibarra, H. Arasanz, G. Fernandez-Hinojal, M. Gato-Canas, B. Hernandez-Marin, M. Martinez-Aguillo, M. J. Lecumberri, A. Fernandez, L. Teijeira, R. Vera, G. Kochan, D. Escors
The paper identifies baseline circulating highly-differentiated CD4 T cells as predictors of response or hyperprogression to PD-L1/PD-1 blockade therapy in lung cancer patients.
bioRxiv · May 22, 2018Cancer Biology